Literature DB >> 12185480

Surface markers of platelet function in idiopathic nephrotic syndrome in children.

Marcin Tkaczyk1, Zbigniew Baj.   

Abstract

The objective of the study was to investigate platelet activation markers in whole blood in idiopathic nephrotic syndrome (INS) in children. The study group consisted of 34 children with 45 relapses of INS, 35 children in long-term remission of INS, and 26 healthy controls. Using flow cytometry we measured the percentage of platelet microparticles, platelet-platelet aggregates, and surface expression of CD62P (P-selectin) and CD42b (a component of von Willebrand factor receptor). We found an increased percentage of microparticles and platelet-platelet aggregates, decreased expression of CD42b in the first 2 weeks of INS relapse. CD62P expression was elevated only at the onset of INS relapse when compared with the long-term remission group and healthy subjects. Children in long-term INS remission did not differ from healthy controls. There was no significant correlation between platelet activation markers and selected biochemical factors of blood in children with INS. Activation of the coagulation cascade was confirmed by an elevated serum concentration of F1+2 prothrombin fragment during follow-up. These findings suggest that platelets may contribute independently to the prothrombotic state in the early stages of INS, but their role in triggering relapses remains to be investigated.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12185480     DOI: 10.1007/s00467-002-0865-7

Source DB:  PubMed          Journal:  Pediatr Nephrol        ISSN: 0931-041X            Impact factor:   3.714


  17 in total

1.  Platelet-derived growth factor and platelet profiles in childhood nephrotic syndrome.

Authors:  Anna M Wasilewska; Walentyna M Zoch-Zwierz; Barbara Tomaszewska; Anna Biernacka
Journal:  Pediatr Nephrol       Date:  2004-10-13       Impact factor: 3.714

2.  Low protein Z levels in children with nephrotic syndrome.

Authors:  Ozan Ozkaya; Kenan Bek; Tunc Fişgin; Yuksel Aliyazicioğlu; Sevinc Sultansuyu; Yonca Açikgöz; Davut Albayrak; Kemal Baysal
Journal:  Pediatr Nephrol       Date:  2006-06-30       Impact factor: 3.714

Review 3.  Chronic kidney disease and venous thromboembolism: epidemiology and mechanisms.

Authors:  Keattiyoat Wattanakit; Mary Cushman
Journal:  Curr Opin Pulm Med       Date:  2009-09       Impact factor: 3.155

Review 4.  Epidemiology and pathophysiology of nephrotic syndrome-associated thromboembolic disease.

Authors:  Bryce A Kerlin; Rose Ayoob; William E Smoyer
Journal:  Clin J Am Soc Nephrol       Date:  2012-02-16       Impact factor: 8.237

5.  Tissue factor pathway inhibitor in childhood nephrotic syndrome.

Authors:  Mohamed M Al-Mugeiren; Abdel Galil M Abdel Gader; Saud A Al-Rasheed; Abdullah A Al-Salloum
Journal:  Pediatr Nephrol       Date:  2006-03-31       Impact factor: 3.714

6.  Cyclosporin A does not affect platelets in children with idiopathic nephrotic syndrome.

Authors:  Marcin Tkaczyk; Zbigniew Baj; Michał Nowicki
Journal:  Pediatr Nephrol       Date:  2004-10-28       Impact factor: 3.714

7.  Exosome Biogenesis and Lysosome Function Determine Podocyte Exosome Release and Glomerular Inflammatory Response during Hyperhomocysteinemia.

Authors:  Dandan Huang; Guangbi Li; Owais M Bhat; Yao Zou; Ningjun Li; Joseph K Ritter; Pin-Lan Li
Journal:  Am J Pathol       Date:  2021-10-27       Impact factor: 4.307

Review 8.  Extracellular Vesicles in Renal Diseases: More than Novel Biomarkers?

Authors:  Uta Erdbrügger; Thu H Le
Journal:  J Am Soc Nephrol       Date:  2015-08-06       Impact factor: 10.121

Review 9.  Platelet abnormalities in nephrotic syndrome.

Authors:  Benedicte Eneman; Elena Levtchenko; Bert van den Heuvel; Chris Van Geet; Kathleen Freson
Journal:  Pediatr Nephrol       Date:  2015-08-13       Impact factor: 3.714

10.  Thrombotic complications in childhood-onset idiopathic membranous nephropathy.

Authors:  Chrystal U Louis; Bruce Z Morgenstern; Lavjay Butani
Journal:  Pediatr Nephrol       Date:  2003-10-30       Impact factor: 3.714

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.